Rehmannioside A

Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, 2C9 and 2D6, with IC₅₀ values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases^[1][2][3][4]. In Vitro: Rehmannioside A (0-100 μM; 24 h) can improve high-glucose-induced decrease in cell viability and inhibit apoptosis and oxidative stress in HK2 cells (increasing the activities of SOD and CAT, reducing the levels of MDA, and decreasing LDH release and ROS production). The mechanism is involved in the inhibition of p38 MAPK and ERK1/2 phosphorylation^[1].
Rehmannioside A (0-80 μM; 48 h) inhibits the release of pro-inflammatory mediators and promotes M2 polarization in LPS (HY-D1056)-treated BV2 cells. The mechanism is related to the inhibition of NF-κB and MEK signaling pathways^[2].
Rehmannioside A (80 μM; 48 h) reduces neuronal apoptosis and restores the expression of anti-apoptotic protein Bcl-2 in the co-culture system of PC12 and BV2 cells^[2]. In Vivo: Rehmannioside A (80 mg/kg; intraperitoneal injection; 28 days) exerts a beneficial effect in a rat model of spinal cord injury^[2].